KIF5B-RET fusions in lung adenocarcinoma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22327624.
- Also identified by DOI 10.1038/nm.2644 and PMC identifier 6430196.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET oncogene, which are present in 1-2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing. The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation of LADC because it segregates from mutations or fusions in EGFR, KRAS, HER2 and ALK, and a RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells.
Medical subject headings
- Adenocarcinoma
- Kinesins
- Lung Neoplasms
- Oncogene Proteins, Fusion
- Proto-Oncogene Proteins c-ret